Tag - URGN

Developments

FDA approves Urogen Pharma’s urothelial cancer drug

The FDA approved UroGen Pharma’s (NASDAQ:URGN) mitomycin gel for the treatment of low-grade upper tract urothelial cancer (UTUC). The gel, which will be marketed under the brand name Jelmyto, inhibits DNA transcription...

April 15, 2020

Developments

Urogen Pharma reports data from two urinary tract cancer trials

UroGen Pharma (NASDAQ:URGN) reported results from its Phase 3 and Phase 2b trials of its mitomycin gel in patients with low-grade upper tract urothelial cancer (UTUC) and intermediate risk low-grade non-muscle invasive...

September 25, 2019

Tag - URGN

FDA approves Urogen Pharma’s urothelial cancer drug

Urogen Pharma reports data from two urinary tract cancer trials

General

More